{
  "docId": "019de071-4ec1-761e-bce7-779cb9a1fe78",
  "docSlug": "bd64755c9d094dce862ec77cfb2b1978",
  "documentTitle": "TScan Therapeutics | IPO Presentation Deck | 43 slides",
  "authorId": "tscan-therapeutics",
  "authorName": "TScan Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 43,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide uses a stylized 'T' graphic with a timeline-like bullet structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-4ec1-761e-bce7-779cb9a1fe78/4",
  "deckHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78",
  "deckJsonHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78.json",
  "deckAnchorHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0,
        "y": 0.2
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bc2f091-a001-45a1-840f-712da7011088",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.65,
        "x": 0.28,
        "y": 0.22
      },
      "kind": "list",
      "text": "Proprietary Target and TCR Discovery Platforms: Enables 'multiplexed' TCR-T therapy; Robust Pipeline in Cancer: Liquid tumor program – 2 INDs, Q4 2021, Solid tumor program – 3 INDs, H2 2022; 1 IND, 2023; Non-Viral Cell Manufacturing: Enables 'enhanced' T cell engineering; Strategic Partnerships: Novel oncology target partnership with Novartis; Strong Investor Support: $160M from RA Capital, Blackrock, Novartis and others",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "deba56d9-242b-4190-8179-41a310ed0429",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.25,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "TScan highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b2d45e4-167a-432d-ab6f-2f21a21496a1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "dfdd1301-a650-4056-b3ac-1167faf32a57",
      "evidence": "This slide is titled 'TScan highlights' and contains a list/bullet of key points, which is typical of an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}